MedTrace Logo

Growth Differentiation Factor 15 in ICU Acquired Muscle Weakness

NCT06713746 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2024-12-09

No results posted yet for this study

Summary

Intensive care unit -acquired weakness (ICU- AW) is a common consequence linked to a worse outcome as evidenced by prolonged mechanical ventilation, longer ICU stays, greater mortality rates and a lower quality of life for survivors, so early detection and treatment of ICU-AW are critical. However, there is no "gold standard" currently available for assessing and diagnosing ICU-AW. It's crucial to develop diagnostic methods that enable for early detection and risk stratification in all critically ill patients, such as:

GDF-15 (growth differentiation factor-15) is thought to be a mediator of muscle atrophy because its level increases in the muscular atrophy As a result, measuring GDF-15 seems promise for diagnosing muscle atrophy.

Conditions

  • Muscle Weakness

Interventions

DIAGNOSTIC_TEST

growth differentiation factor 15

rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta

Sponsors & Collaborators

  • Minia University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-10
Primary Completion
2024-09-10
Completion
2024-09-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06713746 on ClinicalTrials.gov